Daiwa Securities Group Inc. increased its stake in Zoetis Inc (NYSE:ZTS) by 6.2% during the 3rd quarter, HoldingsChannel reports. The firm owned 20,676 shares of the company’s stock after buying an additional 1,203 shares during the period. Daiwa Securities Group Inc.’s holdings in Zoetis were worth $2,576,000 as of its most recent filing with the Securities and Exchange Commission.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
Other hedge funds also recently modified their holdings of the company. Symmetry Partners LLC boosted its stake in shares of Zoetis by 24.3% during the 3rd quarter. Symmetry Partners LLC now owns 5,962 shares of the company’s stock worth $743,000 after acquiring an additional 1,166 shares during the last quarter. Keybank National Association OH boosted its stake in shares of Zoetis by 4.4% during the 3rd quarter. Keybank National Association OH now owns 447,229 shares of the company’s stock worth $55,720,000 after acquiring an additional 18,857 shares during the last quarter. Appleton Partners Inc. MA boosted its stake in shares of Zoetis by 0.9% during the 3rd quarter. Appleton Partners Inc. MA now owns 86,734 shares of the company’s stock worth $10,806,000 after acquiring an additional 761 shares during the last quarter. Bartlett & Co. LLC boosted its stake in shares of Zoetis by 44.4% during the 3rd quarter. Bartlett & Co. LLC now owns 377 shares of the company’s stock worth $47,000 after acquiring an additional 116 shares during the last quarter. Finally, Aubrey Capital Management Ltd boosted its stake in shares of Zoetis by 7.9% during the 3rd quarter. Aubrey Capital Management Ltd now owns 46,400 shares of the company’s stock worth $5,781,000 after acquiring an additional 3,400 shares during the last quarter. Institutional investors own 89.95% of the company’s stock.
ZTS opened at $117.86 on Friday. The company has a debt-to-equity ratio of 2.74, a quick ratio of 2.87 and a current ratio of 4.17. Zoetis Inc has a fifty-two week low of $78.90 and a fifty-two week high of $130.20. The firm’s fifty day moving average is $125.46 and its 200 day moving average is $116.48. The stock has a market cap of $57.43 billion, a price-to-earnings ratio of 37.65, a price-to-earnings-growth ratio of 2.98 and a beta of 0.88.
Zoetis (NYSE:ZTS) last released its earnings results on Thursday, November 7th. The company reported $0.94 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.06. Zoetis had a net margin of 22.74% and a return on equity of 72.86%. The company had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.58 billion. During the same quarter in the previous year, the company earned $0.83 EPS. Zoetis’s revenue for the quarter was up 7.0% on a year-over-year basis. On average, equities research analysts predict that Zoetis Inc will post 3.57 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Tuesday, October 22nd will be paid a dividend of $0.164 per share. This represents a $0.66 dividend on an annualized basis and a dividend yield of 0.56%. The ex-dividend date of this dividend is Monday, October 21st. Zoetis’s dividend payout ratio (DPR) is 21.09%.
ZTS has been the topic of several analyst reports. Barclays lifted their price target on shares of Zoetis from $120.00 to $135.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Argus set a $140.00 price target on shares of Zoetis and gave the stock a “buy” rating in a research note on Wednesday, September 4th. Morgan Stanley lifted their price target on shares of Zoetis from $100.00 to $136.00 and gave the stock an “equal weight” rating in a research note on Monday, September 30th. Stifel Nicolaus set a $140.00 price target on shares of Zoetis and gave the stock a “buy” rating in a research note on Friday, September 13th. Finally, Goldman Sachs Group initiated coverage on shares of Zoetis in a research note on Monday, September 9th. They set a “conviction-buy” rating and a $145.00 price target on the stock. Eight investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. Zoetis currently has a consensus rating of “Buy” and a consensus target price of $126.75.
In other Zoetis news, EVP Clinton A. Jr. Lewis sold 6,123 shares of Zoetis stock in a transaction on Monday, October 14th. The shares were sold at an average price of $128.62, for a total value of $787,540.26. Following the sale, the executive vice president now directly owns 39,141 shares in the company, valued at approximately $5,034,315.42. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Kristin C. Peck sold 11,500 shares of Zoetis stock in a transaction on Monday, August 12th. The shares were sold at an average price of $123.22, for a total transaction of $1,417,030.00. Following the completion of the sale, the executive vice president now owns 48,877 shares in the company, valued at $6,022,623.94. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 34,332 shares of company stock worth $4,258,182. 0.29% of the stock is owned by corporate insiders.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Read More: How is a price target determined?
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).